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PEMBANGUNAN DAN PENILAIAN SUATU FORMULASI MATRIKS 
PELEPASAN TERKA W AL BAGI GLIKLAZIDA 
ABSTRAK 
Dua polimer hidrofobik, Kollidon® SR dan Eudragit® RSPO serta dua polimer 
hidrofilik hidroksil propil metilselulosa, iaitu HPMC KIOOLV dan HPMC Kl5M, 
telah dikaji sebagai bahan pembentukan matriks tablet untuk mengawal pelepasan 
gliklazida. Pelepasan drug dapat diubahsuai mengikut suatu gaya yang boleh 
diramalkan dengan mengubah kandungan polimer, di mana peningkatan kandungan 
polimer menghasilkan kadar pelepasan yang lebih tertahan. Pada kandungan polimer 
yang sama, tablet yang disediakan dengan menggunakan HPMC K 15M m~mpunyai 
kadar pelepasan drug yang paling tertahan, diikuti oleh Kollidon® SR, HPMC 
KlOOLV dan akhimya Eudragit® RSPO. Perbandingan antara beberapa gred HPMC 
juga menunjukkan bahawa pelepasan drug yang paling tertahan dapat dicapai dengan 
menggunakan HPMC KlOOM, diikuti oleh HPMC Kl5M, HPMC K4M, HPMC 
KlOOLV, HPMC E4M dan HPMC E15. Amaun dan komposisi cecair granulasi serta 
julat saiz partikel polimer turut memberi kesan yang signifikan terhadap pelepasan 
drug daripada matriks yang mengandungi 30% Kollidon® SR.. Peningkatan amaun 
cecair granulasi, peningkatan nisbah isopropil alkohol kepada air serta peningkatan 
nisbah Kollidon® SR yang mempunyai saiz partikel yang lebih besar boleh 
menyebabkan penurunan dalam kadar pelepasan drug. 
Pelepasan gliklazida daripada formulasi yang mengandungi 30% Kollidon® SR 
bergantung kepada pH, di mana kadar pelepasan yang tertinggi diperolehi dengan pH 
XXX 
7.4, diikuti dengan pH 1.2 dan drug dilepaskan dengan kadar yang terendah pada pH 
4.0. Akan tetapi, apabila Kollidon® SR dikaji dengan menggunakan dua drug 
hidrofilik yang lain, iaitu diltiazem HCI dan theophylline, kadar pelepasan kedua-dua 
drug tersebut adalah lebih cepat berbanding dengan gliklazida apabila dikaji pada 
ketiga-tiga nilai pH yang tersebut di atas. Tambahan pula, kadar pelepasan gliklazida 
yang rendah serta bergantung kepada pH gagal diatasi apabila maltodekstrin, kalsium 
fosfat dibasic atau Plasdon® S-630 digabungkan ke dalam matriks Kollidon® SR. 
Justeru itu, Kollidon® SR tidak sesuai dijadikan sebagai bahan pembentukan matriks. 
HPMC KlOOLV dikaji selanjutnya untuk menilai kesesuaiannya untuk digunakan 
sebagai bahan matriks untuk gliklazida. Satu formulasi yang mengandungi 30% 
HPMC KlOOLV dan 30% kalsium fosfat dibasic boleh menghasilkan profit 
pelepasan drug yang hampir serupa atau berpadanan dengan profil sediaan rujukan, 
Diamicron:ID MR pada pelbagai pH yang berlainan apabila dinilai dengan 
menggunakan fa.ktor differential (F1) dan faktor similarity (F2). Kaedah penyediaan 
tablet yang berlainan, iaitu, granulasi basah, pemampatan terus dan granulasi kering 
juga boleh mempengaruhi kadar pelepasan gliklazida. Profil pelepasan drug daripada 
tablet yang disediakan dengan granulasi basah adalah lebih setara dengan, profil 
Diamicron® MR, dan ini menunjukkan bahawa kaedah ini lebi~ sesuai digunakan 
untuk penyediaan tablet. Tambahan pula, profil pelepasan drug untuk tablet yang 
dihasilkan dengan menggunakan kaedah granulasi basah didapati stabil selepas 6 
bulan. 
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DEVELOPMENT AND EVALUATION OF A MATRIX 
CONTROLLED-RELEASE FORMULATION OF GLICLAZIDE 
ABSTRACT 
Two hydrophobic polymers, Kollidon® SR and Eudragit® RSPO as well as two 
hydrophilic hydroxypropyl methylcellulose polymers, namely, HPMC KlOOLV and 
HPMC Kl5M were evaluated as matrix tablet forming materials for sustaining the 
release of gliclazide. It was found that drug release could be modified in a 
predictable manner by varying the content of the polymers, whereby increasing the 
polymer content resulted in a more sustained rate of drug release. At the same 
polymer content, the drug release was most sustained with tablets prepared using 
HPMC Kl5M, followed by Kollidon® SR, HPMC Kl OOLV and lastly Eudragit® 
RSPO. A similar comparison of several grades of HPMC showed that the drug 
release was more sustained with HPMC Kl OOM, followed by HPMC Kl5M, HPMC 
K4M, HPMC KIOOLV, HPMC E4M and HPMC El5. The amount and the 
composition of granulation fluid as well as the particle size range of the polymer 
were also found to have a significant impact on the drug release from a 30% 
Kollidon® SR matrix. Increasing the amount of granulation fluid and the ratio of 
isopropyl alcohol to water as well as using a higher proportion of Kollidon® SR 
polymer with larger particle size led to a decrease in the rate of drug release. 
The gliclazide release from a formulation containing 30% of Kollidon® SR was 
found to be pH-dependent, with the highest release rate occurring at pH 7 .4, followed 
by at pH 1.2 and the slowest at pH 4.0. However, when Kollidon® SR was evaluated 
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using two other hydrophilic drugs, namely diltiazem HCl and theophylline, their 
release rate was found to be faster than that of gliclazide in all the three pH values. 
Incorporation of maltodextrin, dibasic calcium phosphate or Plasdon® S-630 into the 
Kollidon® SR matrix also failed to overcome the slow and pH-dependent release of 
gliclazide. Thus, Kollidon® SR was found not suitable to be used as matrix forming 
materials. 
HPMC KlOOLV was further studied for its suitability to be used as the matrix 
materials for gliclazide. A formulation with 30% HPMC KlOOLV and 30% dibasic 
calcium phosphate could produce drug release profiles quite similar or matching to 
those of reference preparation, Diamicron® MR at the different pH conditions when 
evaluated using the differential (F 1) and similarity (F2) factors. Different methods of 
tablet preparation, namely, wet granulation, direct compression and dry granulation 
were also found to affect the rate of gliclazide release. The drug release profiles of 
tablets prepared "by wet granulation were more comparable to those of Diamicron® 
MR, revealing that this method was preferred for tablet preparation. Moreover, the 
drug release profiles of the tablets produced using the wet granulation method was 
found to be stable after 6 months of study. 
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CHAPTER 1: INTRODUCTION 
1.1 GENERAL PRINCIPLE 
To date, oral administration remains the most preferred mode for delivery of 
therapeutic agents due to its ease and convenience to the patients. Conventional 
dosage forms are generally designed not only to produce maximum physical and 
chemical stability, but also to give maximal drug bioavailability by optimizing the 
rate and extent of drug absorption. Whilst such dosage forms have been useful, they 
often give rise to big fluctuations in peak and trough plasma drug level when given 
repeatedly (Vergnaud, 1993). High peak drug levels may give rise to undesirable side 
effects while excessively low trough levels may cause loss of therapeutic levels. 
Thus, maintenance of steady state drug levels with minimal fluctuations has become 
an important issue in drug delivery, especially with drugs of relatively narrow 
therapeutic indices. 
Another problem with conventional dosage forms, especially if the contained drug 
has a short biological half life, is that the drug has to be given more frequently, for 
example 2 or 3 or 4 times a day to obtain the desired therapeutic response (Dash & 
Cudworth, 1998). This will cause great inconvenience to the patjent and hence may 
give rise to poor compliance (Vergnaud, 1993). To overcome these problems, several 
technical advancements have been made in the development of new drug delivery 
systems capable of controlling the rate of drug delivery, sustaining the duration of 
therapeutic activity and/or targeting the delivery of drug to a tissue (Chien, 1983; 
Patel & Amiji, 1996; Srivastava et al., 2005; Streubel eta!., 2006). 
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1.2 HISTORICAL REVIEW OF THE DEVELOPMENT OF 
CONTROLLED-RELEASE DELIVERY SYSTEM 
The concept of controlling the drug release using a coated solid dosage form to 
overcome the bitter taste and unpleasant odour of drugs was mentioned by Razes 
between the year of 850 and 923, as cited by James et al. (1986). Nevertheless, one 
of the first notions towards the production of oral controlled-release dosage forms 
was only initiated by the German dermatologist, Paul G. Unna in 1884, who stated 
that if the pills were protected by keratin, they would not dissolve until they had 
emptied from the stomach (Helfand & Cowen, 1982). According to the review by 
Saunders (1961 ), it was only in the year 1944 that Romansky and Rittman 
successfully introduced a water-soluble salt of an antibiotic formulated in peanut oil 
with 4% wax for intramuscular injection, in which the release of the antibiotic was 
extended as a result of increased viscosity. 
1.3 ORAL-CONTROLLED-RELEASE DOSAGE FORM 
The term controlled-release delivery system refers to a system that provides 
continuous delivery of the contained drug for absorption in a predictable and 
reproducible rate (over an extended period of time) following a single-dose 
administration (Chien, 1992). Terminologies such as controllep-release, prolonged 
action, modified release and sustained release have also been used interchangeably 
with extended release to describe such dosage form or delivery system. A typical 
controlled-release delivery system is designed to provide a constant or an almost 
constant plasma drug level with less fluctuation via slow release of the contained 
drug over an extended period of time. In practical terms, an oral controlled-release 
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dosage form should allow a reduction in dosing frequency of the contained drug 
compared to the conventional dosage form (Qiu & Zhang, 2000). 
The first truly effective oral controlled-release drug delivery system was marketed by 
Smith, Kline and French Laboratories (SK&F), applying the patented Blythe's 
concept (Blythe, 1956). It was spansule® Capsule, an oral controlled-release dosage 
form which worked via enteric coating. As reviewed by Ranade and Hollinger 
(2004), this first oral controlled-release preparation actually consisted of many small 
coated beads placed in a capsule and the beads were designed to release the drug at 
different rates, independent of the gastrointestinal environment. Another system 
using ion exchange resins in the formulation of controlled-release delivery system 
was reported by Saunders (1961 ). Later in 1959, a tablet containing plastic matrices 
called Duretter, was patented (Fryklof, 1959). Since then, many controlled-release 
products with various mechanisms of action were introduced, and given various 
names such as ·extended release, sustained release, prolonged action or long acting 
dosage form. 
1.4 APPROACHES FOR DEVELOPMENT OF ORAL CONTROLLED-
RELEASE DELIVERY SYSTEM 
Several techniques have been utilized in the development of controlled-release drug 
delivery systems. The basic principle works on slowing the rate of drug dissolution 
or release from the dosage form. Generally, there are two approaches to the 
development of controlled-release drug delivery system (Lordi, 1986). The first 
approach is by modifying the physical and/or chemical properties that affect the drug 
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bioavailability, and this approach is suitable only for drug moieties with certain 
functional groups. The second approach is via modification of dosage form design. 
Many methods have been utilized to control the drug release and the commonly used 
methods including using a drug embedded matrix, barrier coating and osmotic 
pressure. A popular oral controlled-release system based on the matrix method is to 
use slowly dissolving polymers. This can be attributed to the recent advancement in 
polymeric materials which has led to a big quantum leap in the progress of most 
controlled-release technologies (Wise, 1984). Three delivery systems have 
dominated today's market of oral controlled-release products, namely, matrix, 
reservoir and osmotic system. Release mechanisms of drug from these systems were 
generally regulated by diffusion, dissolution, bioerosion or degradation and 
generation of osmotic pressure (Ranade & Hollinger, 2004). Thus, these mechanisms 
have been the subject of extensive studies on controlled-release technologies 
(Higuchi, 1961; Higuchi, 1963; Colombo et a/., 2000a; Colombo et a/., 2000b; 
Siepmann & Gopferich, 2001; Grassi & Grassi, 2005). 
1.5 MECHANISMS OF CONTROLLED-RELEASE 
1.5.1 DIFFUSION-CONTROLLED MECHANISM 
Diffusion can be defined as a process by which molecules transfer spontaneously 
from one region to another in order to equalize chemical potential gradient. It is a 
result of random molecular motion with a wide spectrum of physico-chemical 
properties occurring in various conditions and situations (Liu et al., 2006). In 
diffusion controlled mechanism, the control of drug release to the environment is 
achieved by diffusion of drug molecules embedded within a polymeric carrier 
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through an inert membrane barrier as a result of concentration gradient (Higuchi, 
1963). Therefore, it is very common for diffusion controlled devices to exhibit non 
zero-order release due to an increase in diffusional resistance and decrease in 
diffusion area as the release proceeds (Venkatraman et a/., 2000). In general, there 
are two types of diffusion controlled systems, namely, reservoir and matrix systems 
(Jantzen & Robinson, 1996). 
1.5.1(a) RESERVOIR DEVICE 
The reservoir type of device is generally spherical, cylindrical or disk-like in shape 
and consists of a compact drug core surrounded by a non-biodegradable penneable 
membrane through which the drug slowly diffuses (Ranade & Hollinger, 2004). The 
rate at which the drug is released is determined by the thickness and the permeability 
of the membrane (Tsai et a!., 1998). Several factors affect the rate of drug release 
from reservoir type of diffusion controlled device. They include the surface area, 
diffusion coefficient, partition coefficient of the drug between the drug core and the 
membrane, the diffusional pathlength and the concentration gradient across the 
membrane. The release kinetics of this type of system suggests that if the 
concentration of the drug within the reservoir is in constant equilibrium With the 
inner surface of the enclosed membrane, the driving force for diffusional release of 
the drug is constant, and zero-order release kinetics of the drug is obtained (Chien, 
1978; Baker, 1987). If a constant drug concentration cannot be maintained then the 
rate of drug release would decline with a decline in the drug concentration in the 
reservoir. However, there is also a possibility of the reservoir membrane to 
accidentally rupturing, causing a sudden large amount of drug to be released 
following administration (known as drug dumping), resulting in toxic side effects if 
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plasma drug concentration exceeds maximum safety level (Dash & Cudworth, 1998; 
Ranade & Hollinger, 2004). Reservoir diffusional systems have several advantages 
over conventional dosage forms, the former can offer zero-order release kinetics of 
drug and the kinetics can be controlled by changing the characteristics of the polymer 
to suit a particular drug as well as therapy conditions. The inherent disadvantage is 
that, unless the polymer used is biodegradable, the system must somehow be 
removed from the body after the drug has been released (Fish et al., 1993 ). 
l.S.l(b) MATRIX SYSTEM 
In the matrix system, also referred to as the monolithic system, the drug is dispersed 
homogenously throughout the polymer matrix, which can be either hydrophobic or 
hydrophilic (Khan & Reddy, 1997; Viega eta!., 1997; Veiga eta!., 1998; Reza et al., 
2003). Slow diffusion of the drug through the matrix provides sustained release of 
the drug from the delivery system (Danckwerts & Fassihi, 1991). Higuchi has 
provided the theoretical basis for defining drug release from such matrices. In this 
model, drug particles dispersed in the outer layer of the matrix which is exposed to 
the bathing solution will dissolve and then diffuse out of the matrix. This process 
continues with penetration of the dissolution medium into the matrix to further 
dissolve the contained drug, thereby, creating channels through which diffusion of 
the dispersed drug in the inner core can take place. It is therefore obvious that for 
matrix system to be diffusion controlled, the rate of dissolution of drug particles 
within the matrix must be much faster than the diffusion rate of dissolved drug 
leaving the matrix (Jantzen & Robinson, 1996). 
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Drug release from a matrix system can be influenced by porosity and tortuosity of 
the matrix. The release rate is directly proportional to the concentration of the 
dispersed drug in the tablet matrix, the diffusion coefficient and the solubility of the 
drug in the release media (Higuchi, 1961 ). Drug particles that are physically 
embedded in the polymer matrix should be at concentrations high enough to create a 
series of interconnected pores through which the drug can subsequently diffuse 
(Langer & Folkman, 1976). However, the release kinetics of the drug from this 
matrix system will not be constant and it depends on the volume fraction of the drug 
within the matrix. The greater the concentration of dissolved drug within the matrix, 
the greater will be its release rate from the matrix system (Dash & Cudworth, 1998). 
As such, a first order release kinetics is obtained from such matrix systems. Thus, 
unlike the reservoir device, there is minimal risk of drug dumping in case of 
accidental rupture of the membrane (Ranade & Hollinger, 2004). 
1.5.2 DISSOLUTION-CONTROLLED MECHANISM 
The releases of certain drugs are inherently sustained due to their intrinsic low 
aqueous solubility and thus these drugs are natural sustained release products (Hui et 
a/., 1987). Thus, in principle, it would seem possible to prepare sustained release 
preparations for highly water soluble drugs by controlling their· dissolution rate in 
gastrointestinal medium. Generally, either matrix or barrier membrane based 
controlled-release systems are applied to slow down, delay, or control the delivery 
and release rate of drugs. It is well comprehended that the dissolution process 
includes two steps that is the initial detachment of drug molecules from the surface 
of their solid structure to the adjacent liquid interface followed by their diffusion 
from the interface into the bulk liquid medium. Therefore, this process can be 
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manipulated to design controlled-release delivery systems with desired release rate 
and profile (Wang & Shemis, 2006). 
In the dissolution controlled matrix system, the drug is uniformly dispersed within a 
tablet core consisting of a slowly dissolving polymer which forms the matrix, in 
which the polymer can be hydrophobic in nature (e.g. wax, polyethylene, 
polypropylene and ethylcellulose) or hydrophilic matrix (e.g. hydroxypropyl 
cellulose, hydroxypropyl methyl cellulose and sodium carboxy methyl cellulose) 
(Venkatraman et a/., 2000). The rate of drug release is controlled by the rate of 
penetration of the dissolution medium into the matrix. This in tum, can be controlled 
by the porosity of the tablet matrix, the presence ofhydrophobic additives, as well as 
wettability of the tablet and the particle surface (Brossard et al., 1983 ). 
In the dissolution controlled barrier system, the drug particles or granules can first 
be coated with· slowly dissolving polymeric materials and subsequently be directly 
compressed into tablets or put into capsules. One of the principal methods of coating 
a drug is through micro encapsulation. Once the polymeric membrane has dissolved, 
the drug contained inside the membrane is immediately available for dissolution and 
absorption. Thus, the drug release can be controlled by adjusting the thickness and 
the dissolution rate of the polymeric membrane. A more uniformed controlled-
release can be obtained via application of a spectrum of different thicknesses 
(Harris, 1981). Drug release from the coated beads occurs in a progressive manner. 
Beads with the thinnest layers will provide the initial dose, while the maintenance of 
drug level at a later timeframe will be achieved with beads of thicker coatings. This 
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was the principle engaged by the SpansuleQil capsule as discussed in section 1.3 
{Benita & Donbrow, 1982). 
The coating materials can be selected from a wide variety of natural and synthetic 
polymers, depending on the characteristic of the drug to be coated and the desired 
release pattern. The commonly used coating materials include gelatin, camauba 
wax, shellac, cellulose acetate phthalate and cellulose acetate butyrate. In the 
dissolution controlled barrier system, the rate limiting step for drug dissolution is the 
diffusion across an aqueous boundary layer. The solubility of the contained drug 
provides the source of energy for drug release, which is countered by the diffusion 
boundary layer of the stagnant fluid {Theeuwes et al., 1991 ). Besides that, there are 
several factors affecting the rate of drug dissolution, which include the aqueous 
solubility of the drug, the surface area of the dissolving particles or tablet, the 
diffusivity of the drug and the thickness of the boundary layer. 
One of the major setbacks of the dissolution controlled barrier system is the 
difficulty in maintaining a constant drug release. The reasons for such difficulty are 
the surface area changes with time, and the solubility of drugs that are weak acids or 
bases is affected by the variation in pH of the gastrointestinal tract. Nevertheless, a 
synthetic methyl vinyl ether maleic anhydride copolymer which has extraordinary 
sensitivity to the surrounding pH has been introduced. This polymeric system is 
completely soluble in the intestine but not soluble in the stomach, thus, can be used 
in oral controlled-release drug delivery system when absorption at a specific site of 
the gastrointestinal tract is desired. Also the zero-order drug release at a particular 
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site of the gastrointestinal tract can be obtained by maintaining the pH of the system 
(Heller & Trescony, 1979). 
1.5.3 EROSION-CONTROLLED MECHANISM 
In erosion controlled drug delivery system, the drug particles are distributed 
uniformly throughout the polymer matrix and the rate of drug release depends on the 
erosion rate of the polymer. When erosion is faster than drug diffusion, the drug 
release is controlled by erosion. The difference between erodible systems and non-
erodible systems is that the structure/mass in a non-erodible system remains 
unchanged with time and the drug is released by diffusion, while the structure or 
mass in an erodible system decreases with time which makes zero-order release 
unlikely (Katzhendler, 1997). Erosion can take place through the whole matrix, 
referred to as bulk erosion, or be limited to the matrix surface, termed as surface 
erosiOn. 
Bulk erosion is very complex because water penetration through the matrix is much 
faster than polymer degradation, leading to a rapid hydration of the internal core of 
matrix and digestion throughout the whole matrix. This results in concurrent drug 
diffusion and matrix erosion (Siepmann & Gopferich, 2001).· Subsequently, the 
weight of the polymer decreases steadily and the matrix permeability increases as a 
function of time. However, the matrix maintains its original shape and mass until up 
to approximately 90% is degraded, then only matrix dissolution and mass loss starts 
(Sinha & Trehan, 2003). In bulk erosion release system, the kinetics of the drug is 
difficult to determine, especially when the matrix disintegrates before drug is 
completely released (Heller, 1984). 
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In surface erosion, degradation takes place only at the matrix boundaries and not in 
the core of the polymer, thus except for the matrix at the boundaries, the physical 
integrity of the matrix is preserved and a consistent degradation rate of the polymer 
is obtained (Heller, 1984). Surface erosion can be achieved when the degradation 
rate of the polymer at the matrix surface is much faster than the rate of water 
penetration into the matrix bulk (Langer, 1990). As the drug is dispersed throughout 
the matrix but only a minimal diffusion takes place, the drug release rate is 
determined by the rate of erosion of the matrix surface. Therefore, surface erosion is 
often preferred over bulk erosion because the former is highly reproducible, the drug 
release rate is proportional to the rate of polymer erosion, and can be controlled by 
varying system thickness and the total drug content. Also, surface erosion eliminates 
the possibility of dose dumping, thus improving the safe use of the delivery system. 
Nevertheless, for most biodegradable drug delivery system especially for 
hydrophilic matii.ces, both erosion mechanisms occur together. The relative extent of 
the predominant mechanism depends on the chemical structure of the polymer 
(Mainardes & Silva, 2004). Polymers with reactive functional groups tend to give 
rise to surface erosion, whereas polymers having less reactive functional groups 
commonly show bulk erosion (Siepmann & Gopferich, 2001). However, there are 
exceptions to this general assumption. For example, bulk eroding materials can 
undergo surface erosion if the critical dimensions of the matrix are exceeded (Von 
Burkersroda et a/., 2002). Besides that, in formulations of nano and micro particles, 
the same erosion process takes place regardless of the type of polymer used (Uhrich 
et a/., 1999). A disadvantage of this type of systems is that the release kinetics is 
often difficult to control (Jantzen & Robinson, 1996). 
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1.5.4 SWELLING-CONTROLLED MECHANISM 
Swelling-controlled matrices utilize a combination of both diffusion and dissolution 
mechanisms (Hopfenberg & Hsu, 1978). The drug is dispersed in the polymer, but 
instead of using an insoluble or erodible polymer, a swellable polymer is employed. 
When the polymer loaded with the drug comes into contact with the gastrointestinal 
fluids, it absorbs water and swells without being dissolved. The swelling further 
increases the entrance of water, causing dissolution of the contained drug, followed 
by diffusion of the dissolved drug out of the swollen networks to the external 
environment. This system usually minimizes the bursting effect as a rapid polymer 
swelling takes place before the drug is being released (Jantzen & Robinson, 1996). 
In swelling controlled delivery systems, the absorption of water causes changes in 
dimensions and physical properties of the matrix, therefore, the changes in the rate 
of drug release is correlated with the degree of swelling. The diffusion coefficient of 
the drug in the matrix is initially very low but increases as the gel absorbs more 
fluids. Thus, the gel layer formation and consequently the rate of drug release are 
highly dependent on the rate of liquid penetration, polymer swelling rate, drug 
solubility and diffusion as well as matrix erosion (Paul & Harris, 1976; Nakagami & 
Nada, 2000). 
The swelling composition of the swellable matrices is divided into three 
components: The first component is the swelling front which clearly separates the 
rubbery region from the glassy region. The second component is the erosion front 
which separates the matrix from the solvent. And the last component is the diffusion 
front located between the swelling and erosion fronts during drug release. The 
position of the diffusion front in the gel phase is dependent on the drug solubility 
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and loading (Colombo et at., 2000b). For swellable matrix delivery systems, 
different models have been reported to describe the diffusion, dissolution and 
swelling processes involved in the drug release mechanism. (Colombo et al,. 1992; 
Colombo et a/,. 1995; Wan et al,. 1995; Colombo et a/,. 1996; Peppas & Colombo, 
1997; Colombo et a/,. 1999; Siepmann et a/,. 1999a; Siepmann et al,. 1999b; 
Siepmann et al,. 1999c; Siepmann et a/,. 2000; Wu et a/., 2005). Nevertheless, the 
essential element of the drug release mechanism is the formation of gel around the 
matrix which assists water penetration and protects matrix disintegration. 
1.5.5 OSMOTIC PUMP SYSTEM 
Osmosis can be defined as the spontaneous movement of a solvent from a region of 
lower solute concentration to a region of higher solute concentration across an ideal 
semi-permeable membrane, which is permeable only to the solvent but impermeable 
to the solute. In recent years, this mechanism was employed for controlling the rate 
of drug release (Theeuwes, 1975; Theeuwes, 1983). In this approach, the unit 
consists of an osmotic core containing an osmotically active drug or a combination 
of an osmotically inactive drug with an osmotically active salt or agent such as 
NaCl, coated with a rigid semi-permeable membrane. 
The uptake of water across the semi-permeable membrane is at a controlled rate that 
causes the device to deliver an equal volume of saturated drug solution out of the 
core through a drilled orifice on the coat. Considering a semi-permeable membrane 
that is permeable to water but not drug (Chien, 1992), the osmotic and hydrostatic 
pressure differences on either side of the semi-permeable membrane will provide the 
driving force to generate controlled-release of the contained drug. The classification 
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of various osmotic delivery systems was discussed in detail by Verma et al. (2000) 
and Conley et a/. (2006). These systems generally appear in two different forms. 
The first form contains the drug in a solid core together with the electrolyte. Both 
the drug and the electrolyte are dissolved by the incoming water, in which the 
electrolyte provides a high osmotic pressure difference. The built-up hydrostatic 
pressure due to the imbibed water can only be relieved by pumping the drug solution 
out of the drilled hole. The second form contains the drug (in solution) in an 
impermeable membrane within the device. The electrolyte surrounding the 
impermeable membrane yields high osmotic pressure to draw water into the device. 
This in turn causes compression of the membrane and drug is pumped out of the 
core through a drilled hole. Both systems have either single or multiple holes bored 
through the membrane to allow drug release. In general, the system can assume a11y 
shape or size, depending on the dosage requirements. 
The semi-permeable membrane exhibits sufficient strength and rigidity to maintain a 
constant volume during pump operation. Delivery rate of the drug is dependent on 
membrane permeability, the osmotic pressure of the core and the solubility of the 
drug (Chien, 1992). Since the release mechanism is based on osmotic pressure, the 
rate of drug release is essentially independent of agitation ~peed, orifice size, 
variation in pH and hydrodynamic conditions (Theeuwes, 1975). The elementary 
osmotic pump benefits from its simple functional design and it is well suited for the 
formulation and delivery of drugs with intermediate water solubility (Theeuwes, 
1984). 
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Besides the typical osmotic pump delivery system described earlier, a controlled 
porosity osmotic pump was described by Zentner et a/. ( 1985). In this system, an 
osmotically active core was coated with a mixture of polymers with differing 
degrees of water solubility. In the presence of water, the soluble components of the 
coating will dissolve, leaving a micro porous film. Subsequently, water can diffuse 
into the core creating an osmotic gradient, which controls the release of drug. The 
rate of drug release depends on the coating thickness, the solubility of the coating 
component, the solubility of drug in the tablet core and the difference in osmotic 
pressure between the core and dissolution medium. 
1.5.6 ION EXCHANGE RESINS 
Ion exchange resin delivery systems generally use water-insoluble crosslinked 
polymers containing groups of exchanging ions to obtain sustained release of drug 
for ionizable drugs. Therefore, these polymers are also known as ion exchange resin. 
These resins contain salt-forming functional groups in repeating positions on the 
resin (Jantzen & Robinson, 1996). They may contain acidic or basic-reacting groups, 
whereby these reacting groups can bind to drugs. Basic drugs are bound to acidic 
cation ion exchangers, while the acidic drugs are bound to basic anion ion 
exchangers. Drug molecules attached to the resins are exchanged for release by 
appropriately charged ions in contact with the ion-exchange groups and the released 
drug molecules diffuse out of the resin. Drug release from the resins depends on 
properties of the resin and the ionic environment, such as pH or electrolyte 
concentration within the gastrointestinal tract (Ranade & Hollinger, 2004). 
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The rate of sustained release of the drug is a result of slow diffusion of drug 
molecules through the resin complex. However, release rate can be controlled by the 
diffusion area, diffusional pathlength and chemical composition as well as rigidity of 
the resin. The release rate can even be further controlled by coating the drug-resin-
complex with a hydrophobic polymer such as ethyl cellulose or waxes, using micro 
encapsulation processes described earlier in Section 1.3.2. Resin-drug complex is 
advantageous for drugs that are highly susceptible to hydrolysis or degradation by 
enzymatic process, since it offers a protective mechanism by temporarily altering the 
substrate. Like all other systems, this approach also has a limitation that the release 
rate is proportional to the concentration of the ions present in the environment, 
indicating that there is a maximum release rate which cannot be further increased. 
Also the release rate of drug can be affected by variability in diet, and water intake 
as well as the individual intestinal content (Eriksen, 1986). 
1.6 ADV ~TAGES OF ORAL CONTROLLED-RELEASE DOSAGE 
FORM 
Oral controlled-release formulations have attained medical acceptance and gained 
popularity due to several therapeutic advantages. More uniform plasma levels of 
drug can be maintained at steady state over an extended period. of time through the 
reduction in fluctuations between peak and trough plasma concentrations (Urquhart, 
1982). Also, the need for frequent drug administration can be minimized to once or 
twice daily, which is particularly advantageous for drugs used in treatment of 
chronic diseases, leading to improved patient compliance and convenience 
(Tinkelman et a/., 1980). The reduced fluctuations in plasma drug levels can help to 
reduce the incidence of adverse side effects, which are common in conventional drug 
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administration (Theeuwes, 1983 ). Moreover, local irritation of the gastrointestinal 
tract due to exposure to high concentration of certain drugs can be minimized 
(Boroda et a/,. 1973). Furthermore, oral controlled-release formulations are useful 
for delivering drug with narrow therapeutic index, in which fluctuation in blood 
level may induce supra therapeutic levels resulting in systemic toxicity, or sub-
therapeutic levels characterized by loss in therapeutic efficacy (Lordi, 1986). The 
overall administration of oral controlled-release products enables increased 
reliability of therapy (Welling & Dobrinska, 1987). 
1.7 DISADVANTAGES OF ORAL CONTROLLED-RELEASE DOSAGE 
FORM 
There are also some disadvantages with controlled-release dosage forms. Prompt 
termination of therapy if significant adverse effects are observed is impossible after 
administration of'the dosage form. Besides that, the physician has less flexibility in 
regulating dosage regimens as the dose has been fixed by the dosage form design. 
The high cost employed in the processes and equipment for manufacturing of 
controlled-release formulations results in more expensive products compared to 
conventional preparations. In addition, the upscale manufacturing procedure 
sometimes causes unpredictable release profile and often ·reduces the drug 
bioavailability due to relatively poor understanding of in vitro and in vivo correlation 
(Gupta & Robinson, 1992). Furthermore, there are other disadvantages such as 
possible dose dumping, increased first-pass metabolism of certain drugs, and the 
effective drug release period is limited and affected by gastrointestinal transit time. 
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1.8 PREPARATION OF TABLETS 
Tablets are solid masses produced by compressing suitably prepared medicaments 
commonly in the form of granules by way of a tab letting machine called presses. The 
tablets can be manufactured in various shapes and sizes. However, they are typically 
circular discs with either flat or convex surfaces. When the tablets are properly 
formulated and manufactured, they ensure that the drug is suitably stable chemically 
and physically and also that it is delivered at an accurate dose. 
1.8.1 TABLET MACHINE 
Tablet machines are designed with the following basic components, a hopper for 
holding and feeding the material to be compressed, a feed frame for distributing the 
material into the dies which respectively define the size and the shape of the tablets, 
punches for compressing material in the dies, and lastly, cam tracks for guiding the 
rotation of the punches. Tablet machines are classified into single punch and multi 
station rotary presses. Although both types of presses accomplish the same task, 
their major differences are the rate of production and mechanical features designed 
to control the compaction process. Although the tablet compressing machinery has 
gone through several era of mechanical modification over the years, the compression 
of material in a couple of moving punches through a stationary die has remained 
unchanged (Banker & Anderson, 1986). The essential alteration of primitive 
equipment has been aimed at increasing the production output rather than creating . 
any fundamental changes in the tableting process. Better control and simplification 
of the manufacturing procedure have been the main benefits as a result of these 
changes. 
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1.8.2 METHODS OF TABLET PREPARATION 
Tablets are usually heterogeneous mixtures containing powders of varying physical 
and chemical properties. During mixing, bonds must be formed between primary 
powder particles, so that they adhere to each other to form larger multi-particle 
entities called granules. These bonds must be sufficiently strong to prevent 
breakdown of the final dried granules back to its powder form in the subsequent 
handling processes. The magnitude of these bonding forces is determined by the size 
of the particles, the structure of granules, the moisture content and the surface 
tension of the liquid. There are three general methods to prepare powder 
materials/granules prior to compression into tablets (Parikh, 1997), namely: 
1.8.2(a) < Direct compression 
In this method, the powdered materials of the tablet are mixed and compressed 
directly without any modification of its physical nature. 
1.8.2(b) Dry granulation 
In this method, the dry powder particles may be brought together mechanically via 
compression to form slugs, or more frequently via compaction by a· roller 
compactor. This method has been utilized when one of the constituents, either the 
drug or the excipients has insufficient cohesive or flow properties to be directly 
compressed into tablets. 
1.8.2(c) Wet granulation 
The wet granulation procedure is usually opted based on the assumption that the 
stability of the drug is not affected by moisture or elevated temperature. The wet 
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granulation procedure includes initial mixing of powder to be incorporated into the 
dosage form and thereafter, the addition of a sufficient amount of a granulating 
liquid to the powder mix in order to obtain granules (Bandelin, 1989). Subsequently, 
the damp mass is screened and then dried. The pharmaceutical granules typically 
have a size range of between 0.2 mm and 4 mm, depending on their intended use. 
The major objectives of granulation are to improve the flow properties and 
compression characteristics of the powder mixture and to prevent particle 
segregation of the constituents. The wet granulation process is preferred over the 
direct compression process based on at least three advantages. Firstly, the wet 
granulation provides the materials to be compressed with better wetting properties, 
particularly in the case of hydrophobic drug substances. The addition of hydrophilic 
excipients makes the surface of a hydrophobic drug more hydrophilic and also 
facilitates disintegration and dissolution. Secondly, the content uniformity of the 
solid dosage forms is generally improved with wet granulation. Finally, the size and 
shape of the particles (comprising the granules to be compressed) are optimized by 
the wet granulation process. The reason for this is that when a dry solid is wet 
granulated; the binder glues particles together so that they agglomerate to form 
granules which are more or less spherical. 
1.8.3 GRANULATION MECHANISM 
The theory of granulation can be expressed using four transitional states (Barlow, 
1968}, known as the pendular, funicular, capillary and droplet or suspension state. 
The mechanism of agglomeration can be described as a gradual change from a 
triphasic stage (air-liquid-solid) in which most granules are in the pendular and 
funicular states to a biphasic (liquid-solid) particulate assembly, in which the 
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granules will be in the capillary and droplet state. Meanwhile, there are five primary 
bonding mechanisms between particles to fonn granules (Rumpf, 1962; Parikh, 
1997). In practice, more than one bonding mechanisms may act simultaneously 
(Parikh, 1997). These mechanisms are discussed below: 
1.8.3(a) Adhesion and cohesion forces 
The availability of liquid between individual primary powder particles to produce a 
very thin immobile adsorption layer can contribute to their bonding among each 
other, thereby effectively reducing the interparticulate space and increasing the 
contact between these particles. The bond strength between these particles is 
dependent on the Van der Waals forces of attraction which is proportional to the 
particle size and inversely proportional. to the square of the distance between 
particles. 
1.8.3(b) Interfacial forces 
Once sufficient liquid is added, the granulation fluid transfonns from an immobile 
surface liquid state to a mobile liquid film state to fonn bridges between the solid 
particles. The tensile strength of these bridges increases as the amount of fluid added 
is increased, where capillary pressure and interfacial forces create strong bonds, 
although reversible after drying. These bonds antecede the solid bridges formation. 
However, mobile liquid films are a precondition to the solid bridges produced by 
binders or the granulating liquid. 
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1.8.3(c) Solid bridges 
Solid bridges are formed during drying of the wet granules or granulating solution 
after wet granulation. These solid bridges may be developed by fusion of particles 
through partial melting at points of contact where high pressure develops, 
particularly at high temperature. This temperature rise can result from either an 
external secondary source or from friction during agglomeration or energy 
conversion. Solid bridges can also be built up from chemical reaction, 
crystallization, hardening of dissolved substances and solidification of melted 
components (Parikh, 1997). 
1.8.3(d) Attractive forces between solid particles 
In the absence of solid bridges formed by binding agent or liquids, there are two 
types of attractive force that can exist between granules, namely the electrostatic and 
Van der Waals forces. The electrostatic force is important for powder cohesion and 
the primary foimation of agglomerates, whereby, this attractive force helps to 
maintain contact of particles long enough for the agglomeration process (Rumpf, 
1962). Meanwhile, the Vander Waals force, which is about four times greater than 
the electrostatic force, contributes significantly to the strength of the granules 
produced by dry granulation (Sherrington & Oliver, 1981 ). The magnitude of the 
Van der Waals force will increase as the distance between adjacent surfaces 
decreases. In slugging or roller compaction, this can be achieved through the 
application of pressure to force the particles together. 
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1.8.3(e) Closed bonds 
Fibers, little platelets, or bulky particles can interlock or fold among each other to 
form closed bonds. Although mechanical interlocking of particles influences the 
strength of agglomerates, its contribution is generally considered small compared to 
other mechanisms. 
1.9 INFLUENCE OF PHYSIOLOGICAL FACTORS ON DOSAGE FORM 
DESIGN AND PERFORMANCE 
In designing an oral dosage form, it is useful to have a general under~tanding of the 
drug disposition within the gastrointestinal tract as well as information pertaining to 
its distribution, integrity or release characteristics from the dosage form since the 
performance of the administered dosage form may be affected by changes in the 
physiological conditions. One of the most important factors affecting the design of 
controlled-release dosage form is the residence time of the dosage form at various 
sites of the gastrointestinal tract which may cause differences in drug bioavailability. 
Furthermore, differences in food status also can have effects on the gastrointestinal 
residence times, as well as drug dissolution from the dosage form. 
The stomach is an organ responsible for storage and mixing. At resting state, the pH 
is acidic with a value of 1 to 3 (Youngberg et a/., 1987). Factors contributing to the 
limited absorption of most drugs from the stomach include the limited surface area of 
0.1 m2 to 0.2 m2, the lack of villi on the mucosal surface, the presence of a relative 
thick layer of mucous on the stomach lining and the short residence time in the 
stomach. Unlike the stomach, the small intestine on the other hand with pH varying 
between 4.0 and 7.4 (depending on location), has a great number of villi on its 
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mucosal surface, imparting a huge surface area of between 200 m2 to 500 m2 
(Davenport, 1977), and hence rendering it to be the essential region for absorption of 
most drugs. There is a progressive decrease in the surface area from the proximal 
region to the distal region of the small intestine. Therefore, the proximal region of 
the small intestine is considered the most important site for drug absorption. Hence, 
in order to achieve good bioavailability, the drug should be targeted for absorption 
from this region of the small intestine . 
The principal function of the colon is to store indigestible food residues. The luminal 
content of the colon is much more viscous than that of the small intestine; with pH 
above 7 or as high as 8. The colonic mucosal surface lacks villi; its exposed surface 
area for absorption is thus reduced. However, in the distal part of the colon, the 
insignificant drug absorption is attributable to the remaining drug being embedded in 
the semisolid foecal matter (Hirtz, 1984). In general, the colonic drug absorption is 
incomplete and erratic (Kock-weser & Schechter, 1981; Gruber eta/., 1987). 
The gastric motility is one of the important factors affecting the in vivo performance 
of controlled-release dosage forms. There are two distinct patterns of gastrointestinal 
tract motility, namely the digestive fed mode and the inter-digestive fasted mode 
(Quigly et al., 1984), in which the pattern and force of the motility may be different 
depending on the food states (Azpiroz & Malagelada, 1984). The fasting 
gastrointestinal motility is characterized by a cyclic pattern that originates from the 
foregut and propagates to the terminal ileum. The cycle can be categorized into four 
manifest phases. Phase I represents an inactive period with no electrical activity and 
no contractions. Phase II is the period of random spike activities or intermittent 
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